The efficacy of TMZ for the treatment of glioblastoma and neuroendocrine tumors is correlated with the expression of O(6)-methylguanine-DNA methyltransferase (MGMT) and/or MGMT promoter methylation [75, 97]. This evidence concerns the gene MGMT and neuroendocrine neoplasm.